Neuland Laboratories Limited announced its unaudited financial results for the quarter and half year ended September 30, 2026. The company reported a revenue of ₹44,965.69 lakhs for the quarter and ₹1,09,123.40 lakhs for the half-year. Additionally, the Board of Directors approved a capital expenditure of ₹47.1 crores for the acquisition of land for future capacity expansion.
Neuland Laboratories Announces Q2 and H1 2026 Financials
Neuland Laboratories Limited has disclosed its unaudited financial results for the quarter and half-year period concluding on September 30, 2026. The company reported a revenue from operations of ₹44,965.69 lakhs for the quarter ended September 30, 2026. For the half-year ended September 30, 2026, the revenue from operations stood at ₹1,09,123.40 lakhs.
Key Financial Highlights
The consolidated financial statement shows total income for the quarter at ₹45,715.22 lakhs and for the half-year at ₹1,10,722.10 lakhs. Total expenses for the quarter amounted to ₹38,817.40 lakhs, resulting in a profit before tax of ₹6,897.82 lakhs. For the half-year, total expenses were ₹84,039.58 lakhs, with a profit before tax of ₹26,682.52 lakhs. The profit for the period/year stood at ₹5,127.38 lakhs for the quarter and ₹19,885.79 lakhs for the half-year.
Capital Expenditure for Expansion
In a significant strategic move, the Board of Directors also approved a capital expenditure of ₹47.1 crores. This expenditure is earmarked for the acquisition of a land parcel measuring 6 acres and 0.00 guntas, located at Domadugu Village, Sangareddy District, Telangana. This acquisition is intended for future capacity expansion and will be financed through internal accruals.
Board Meeting Details
The Board meeting, during which these results and approvals were finalized, commenced at 9:30 a.m. and concluded at 3:34 p.m. on November 3, 2026. The company has confirmed that the detailed financial results and limited review reports are enclosed with this disclosure.
Source: BSE
